LivingGLP1
Study S002732

FINErenone druG Utilization Study and Assessment of Temporal Changes Following Availability of Different Treatment Options in Patients With Chronic Kidney Disease and Type 2 Diabetes

ClinicalTrials.gov record

Registration

Registration
NCT05526157
Acronym
FINEGUST
Study type
OBSERVATIONAL
Status
COMPLETED
Enrollment
50000
Start
2022-10-01
Primary completion
2024-09-05
Lead sponsor
Bayer
Conditions
Chronic Kidney Disease; Type 2 Diabetes Mellitus
Interventions
DRUG:Finerenone (Kerendia, BAY 948862); DRUG:Sodium-glucose cotransporter 2 inhibitors (SGLT2i); DRUG:Glucagon-like peptide-1 receptor agonists (GLP 1 RA); DRUG:Steroidal mineral corticoid receptor antagonists (sMRA); DRUG:Non-steroidal mineral corticoid receptor antagonists (nsMRA)
Results posted
FALSE
Individual participant data sharing
NO

Registered primary outcomes

  • Descriptive summary of baseline patient characteristics [Baseline study periods I and II]
  • Descriptive summary of patient comorbidities [Baseline study periods I and II]
  • Descriptive summary of patient comedications [Baseline study periods I and II]

Linked records (4)

Automatic links, confirmed or rejected during screening. A record citing this registration may be a secondary analysis, a commentary or a review that mentions the trial.
RecordTitleYearDesignIdentifiersLink basis
R0003350Temporal Changes in SGLT2 Inhibitor and GLP-1 Receptor Agonist Use in Patients with Chronic Kidney Disease and Type 2 Diabetes, 2012-2023: A US Cohort Study.
Johannes CB, Diabetes therapy : research, treatment and education of diabetes and related disorders
2026Nonrandomized studyPMID 41364416DOIcites ClinicalTrials.gov:NCT05526157; registry reference DERIVED:41364416
R0003904Utilization and clinical characteristics of patients with type 2 diabetes and chronic kidney disease prescribed finerenone in the United States.
Kovesdy CP, Journal of clinical & translational endocrinology
2026Nonrandomized studyPMID 41810084DOIcites ClinicalTrials.gov:NCT05526157
R0004875Clinical Profile and Treatment Patterns in Individuals with Type 2 Diabetes and Chronic Kidney Disease Who Initiate a GLP-1 Receptor Agonist: A Multinational Cohort Study.
Pladevall-Vila M, Diabetes therapy : research, treatment and education of diabetes and related disorders
2025Nonrandomized studyPMID 40106222DOIcites ClinicalTrials.gov:NCT05526157
R0046884#2505 CHARACTERISTICS OF MEDICATION-INITIATOR COHORTS OF PATIENTS WITH CHRONIC KIDNEY DISEASE AND TYPE 2 DIABETES IN JAPAN: A REPORT FROM FOUNTAIN PLATFORM
Yuichiro Yano, Nephrology Dialysis Transplantation
2023Nonrandomized studyDOIcites ClinicalTrials.gov:NCT05526157